Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for the treatment of brain and ovarian cancer at FNN's Investor Event.
- Cancer drug developer for clinical trails in ovarian cancer and brain cancer
- Planned collaborations for other forms of cancer
- Strong team with experience in big pharma and early-stage biotech
- Glioblastoma (GBM) - most common and aggressive form of brain cancer
- New treatment options needed for brain cancer
- NASDAQ & ASX listed
For more, watch CEO and Executive Director Dr James Garner present.